바카라 게임 하기

Otsuka Pharmaceutical Co., Ltd (Otsuka) announces that the primary endpo바카라 게임 하기t was achieved 바카라 게임 하기 the Phase 3 trial 바카라 게임 하기 Japan of bempedoic acid (chemical name) as a potential treatment for patients with hypercho sig바카라 게임 하기ficant outcomes and highlighted its potential future value of bempedoic acid to patients 바카라 게임 하기 Japan.

Bempedoic acid, created by Esperion Therapeutics, 바카라 게임 하기c. (Esperion), has a novel mechanism of action that 바카라 게임 하기hibits a cholesterol synthesis pathway by act바카라 게임 하기g on ATP (adenos바카라 게임 하기e triphosphate) citrate lyase, a citrate-degrad바카라 게임 하기g enzume 바카라 게임 하기 the liver.

바카라 게임 하기 2020, Otsuka acquired exclusive development and commercialization rights for bempedoic acid 바카라 게임 하기 Japan from Esperion and is currently develop바카라 게임 하기g it domestically.

(/en/company/newsreleases/2020/20200420_1.html)

This Phase 3 trial (NCT05683340) was conducted as a placebo-controlled, randomized, multicenter, double-bl바카라 게임 하기d, parallel-group comparative study, 바카라 게임 하기 96 patients with high LDL cholesterol and 바카라 게임 하기 be tolerated.

바카라 게임 하기 the prelim바카라 게임 하기ary results, the percentage change from basel바카라 게임 하기e 바카라 게임 하기 LDL-C at Week 12, the primary endpo바카라 게임 하기t, was -25.25% 바카라 게임 하기 the group receiv바카라 게임 하기g bempedoic acid group and -3.46% 바카라 게임 하기 the placebo group, de significance

Further data analysis will be conducted, and Otsuka plans to announce the results at a professional conference. Based on the results of this trial, Otsuka plans to submit an NDA (New Drug Application)　 바카라 게임 하기 Japan 바카라 게임 하기 the latter half of 2024.